rttnews.com
Negativewww.rttnews.com ·
hemab therapeutics closes upsized 346 7 million ipo to advance rare bleeding disorder pipeline
TAX_DISEASE_FACTOR_VII_DEFICIENCYTAX_DISEASE_DEFICIENCYTAX_DISEASE_BLEEDING_DISORDERWB_1428_INJURY
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedHemab Therapeutics, a biotech focused on rare bleeding disorders, completed an upsized IPO raising $346.7M. The IPO provides capital to advance its pipeline, but the stock dropped 25% on debut, indicating weak investor demand. The commercial mechanism is the company's access to public equity funding for R&D; no direct impact on product prices or supply chains yet. Sector: PHARMA_BIOTECH. Impact is company-specific, not global or regional.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Hemab Therapeutics raised ~$346.7M in upsized IPO on Nasdaq (COAG).
- IPO priced at $18.00 per share, 19.26M shares sold, underwriters exercised full option.
- Shares closed at $25.34 on first trading day, down 25.47% from IPO price.
- Pipeline includes Sutacimig for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002 for von Willebrand disease.
- Company based in Cambridge, MA and Copenhagen, Denmark.